Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies

NCT02216890 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT02216890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02216890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2014
Completion date
February 15, 2017
Enrollment
38 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse, large b-cell, lymphoma, follicular lymphoma, grade 3, mantle-cell lymphoma, renal cell carcinoma